These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 29125731)

  • 21. Preclinical ImmunoPET Imaging of Glioblastoma-Infiltrating Myeloid Cells Using Zirconium-89 Labeled Anti-CD11b Antibody.
    Nigam S; McCarl L; Kumar R; Edinger RS; Kurland BF; Anderson CJ; Panigrahy A; Kohanbash G; Edwards WB
    Mol Imaging Biol; 2020 Jun; 22(3):685-694. PubMed ID: 31529407
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Radiolabelling and preclinical characterization of
    Burvenich IJG; Goh YW; Guo N; Gan HK; Rigopoulos A; Cao D; Liu Z; Ackermann U; Wichmann CW; McDonald AF; Huynh N; O'Keefe GJ; Gong SJ; Scott FE; Li L; Geng W; Zutshi A; Lan Y; Scott AM
    Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3075-3088. PubMed ID: 33608805
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Practical Immuno-PET Radiotracer Design Considerations for Human Immune Checkpoint Imaging.
    Mayer AT; Natarajan A; Gordon SR; Maute RL; McCracken MN; Ring AM; Weissman IL; Gambhir SS
    J Nucl Med; 2017 Apr; 58(4):538-546. PubMed ID: 27980047
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quantification of PD-L1 Expression with
    Huisman MC; Niemeijer AN; Windhorst AD; Schuit RC; Leung D; Hayes W; Poot A; Bahce I; Radonic T; Oprea-Lager DE; Hoekstra OS; Thunnissen E; Hendrikse NH; Smit EF; de Langen AJ; Boellaard R
    J Nucl Med; 2020 Oct; 61(10):1455-1460. PubMed ID: 32060213
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Noninvasive Imaging and Quantification of Radiotherapy-Induced PD-L1 Upregulation with
    Ehlerding EB; Lee HJ; Barnhart TE; Jiang D; Kang L; McNeel DG; Engle JW; Cai W
    Bioconjug Chem; 2019 May; 30(5):1434-1441. PubMed ID: 30973703
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immuno-SPECT/PET imaging with radioiodinated anti-PD-L1 antibody to evaluate PD-L1 expression in immune-competent murine models and PDX model of lung adenocarcinoma.
    Wen X; Shi C; Zhao L; Yao L; Xu D; Lin X; Su X; Liu T; Zhuang R; Lin Q; Chen H; Guo Z; Zhang X
    Nucl Med Biol; 2020; 86-87():44-51. PubMed ID: 32474281
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of Novel ImmunoPET Tracers to Image Human PD-1 Checkpoint Expression on Tumor-Infiltrating Lymphocytes in a Humanized Mouse Model.
    Natarajan A; Mayer AT; Reeves RE; Nagamine CM; Gambhir SS
    Mol Imaging Biol; 2017 Dec; 19(6):903-914. PubMed ID: 28247187
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ImmunoPET Imaging with 89Zr-Labeled Atezolizumab Enables In Vivo Evaluation of PD-L1 in Tumorgraft Models of Renal Cell Carcinoma.
    Mulgaonkar A; Elias R; Woolford L; Guan B; Nham K; Kapur P; Christie A; Tcheuyap VT; Singla N; Bowman IA; Stevens C; Hao G; Brugarolas J; Sun X
    Clin Cancer Res; 2022 Nov; 28(22):4907-4916. PubMed ID: 36074149
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immuno-PET Imaging of
    Li D; Cheng S; Zou S; Zhu D; Zhu T; Wang P; Zhu X
    Mol Pharm; 2018 Apr; 15(4):1674-1681. PubMed ID: 29502426
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ImmunoPET Imaging of CD146 in Murine Models of Intrapulmonary Metastasis of Non-Small Cell Lung Cancer.
    England CG; Jiang D; Hernandez R; Sun H; Valdovinos HF; Ehlerding EB; Engle JW; Yang Y; Huang P; Cai W
    Mol Pharm; 2017 Oct; 14(10):3239-3247. PubMed ID: 28825843
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
    Rebelatto MC; Midha A; Mistry A; Sabalos C; Schechter N; Li X; Jin X; Steele KE; Robbins PB; Blake-Haskins JA; Walker J
    Diagn Pathol; 2016 Oct; 11(1):95. PubMed ID: 27717372
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PD-L1 Positron Emission Tomography Imaging in Patients With Non-Small Cell Lung Cancer: Preliminary Results of the ImmunoPET Phase 0 Study.
    Hegi-Johnson F; Rudd SE; Wichmann CW; Akhurst T; Roselt P; Sursock S; Trinh J; John T; Devereux L; Donnelly PS; Hicks RJ; Scott AM; Steinfort D; Fox S; Blyth B; Parakh S; Hanna GG; Callahan J; Burbury K; MacManus M
    Int J Radiat Oncol Biol Phys; 2023 Nov; 117(3):675-682. PubMed ID: 37406824
    [No Abstract]   [Full Text] [Related]  

  • 33. PET imaging facilitates antibody screening for synergistic radioimmunotherapy with a
    Ren J; Xu M; Chen J; Ding J; Wang P; Huo L; Li F; Liu Z
    Theranostics; 2021; 11(1):304-315. PubMed ID: 33391476
    [No Abstract]   [Full Text] [Related]  

  • 34. Anti-MET immunoPET for non-small cell lung cancer using novel fully human antibody fragments.
    Li K; Tavaré R; Zettlitz KA; Mumenthaler SM; Mallick P; Zhou Y; Marks JD; Wu AM
    Mol Cancer Ther; 2014 Nov; 13(11):2607-17. PubMed ID: 25143449
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PD-L1 Detection in Tumors Using [(64)Cu]Atezolizumab with PET.
    Lesniak WG; Chatterjee S; Gabrielson M; Lisok A; Wharram B; Pomper MG; Nimmagadda S
    Bioconjug Chem; 2016 Sep; 27(9):2103-10. PubMed ID: 27458027
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ImmunoPET: IMaging of cancer imMUNOtherapy targets with positron Emission Tomography: a phase 0/1 study characterising PD-L1 with
    Hegi-Johnson F; Rudd SE; Wichmann C; Akhurst T; Roselt P; Trinh J; John T; Devereux L; Donnelly PS; Hicks R; Scott AM; Steinfort D; Fox S; Blyth B; Parakh S; Hanna GG; Callahan J; Burbury K; MacManus M
    BMJ Open; 2022 Nov; 12(11):e056708. PubMed ID: 36400733
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessing PD-L1 Expression Level by Radiomic Features From PET/CT in Nonsmall Cell Lung Cancer Patients: An Initial Result.
    Jiang M; Sun D; Guo Y; Guo Y; Xiao J; Wang L; Yao X
    Acad Radiol; 2020 Feb; 27(2):171-179. PubMed ID: 31147234
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Automated radiosynthesis of [
    Wichmann CW; Poniger S; Guo N; Roselt P; Rudd SE; Donnelly PS; Blyth B; Van Zuylekom J; Rigopoulos A; Burvenich IJG; Morandeau L; Mohamed S; Nowak AK; Hegi-Johnson F; MacManus M; Scott AM
    Nucl Med Biol; 2023; 120-121():108351. PubMed ID: 37224789
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CD147-mediated glucose metabolic regulation contributes to the predictive role of
    Li X; Fu Q; Zhu Y; Wang J; Liu J; Yu X; Xu W
    Mol Carcinog; 2019 Feb; 58(2):247-257. PubMed ID: 30320488
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of Anti-LGR5 Antibodies by ImmunoPET for Imaging Colorectal Tumors and Development of Antibody-Drug Conjugates.
    Azhdarinia A; Voss J; Ghosh SC; Simien JA; Hernandez Vargas S; Cui J; Yu WA; Liu Q; Carmon KS
    Mol Pharm; 2018 Jun; 15(6):2448-2454. PubMed ID: 29718672
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.